Biotech: Page 31
-
Stock via Getty Images
ProfileHorizon’s VP of R&D on her ascent in biotech — and bringing other female scientists along for the ride
Elizabeth Thompson is guiding Horizon through new drug approvals while leading the way for young women in STEM.
By Alexandra Pecci • March 8, 2022 -
Stock via Getty Images
Two key factors behind NYC's record-setting rise in healthcare funding
According to a new report, women’s and digital health led to an explosion in funding last year in NYC.
By Robin Robinson • March 7, 2022 -
Explore the Trendline➔
Stock via Getty Images
TrendlineCommercialization, marketing and social media
As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical.
By PharmaVoice staff -
Stock via Getty Images
Are patients happy? This simple question could shake up clinical trials
The migration to DCTs is helping uncover critical gaps in patient experience.
By Kelly Bilodeau • March 4, 2022 -
Permission granted by Andrew Hopkins.
Q&AExscientia scored the largest AI deal with a Big Pharma to date — but it's just getting started
The company’s CEO on the road ahead for AI capabilities in pharma.
By Meagan Parrish • March 4, 2022 -
Diego Camargo/PharmaVoice
Podcast
Woman of the Week: Lyndra Therapeutics' CEO Dr. Trish Hurter
With Lyndra's ultra-long-acting therapies, Hurter and the company are aiming to reinvent medicines.
By Taren Grom • March 2, 2022 -
Diego Camargo/PharmaVoice
The 2022 PharmaVoice 100 — new look, same drive for excellence
Some of the industry’s biggest names have been on our list of honorees. Now it’s time to find this year’s inspiring leaders.
By Taren Grom • Feb. 28, 2022 -
Stock via Getty Images
Q&ACandel's CEO looks to help ignite a new era of cancer treatments
Candel Therapeutics is advancing a next-gen approach in oncology: using viruses to kill cancer cells at the site of injection.
By Taren Grom • Feb. 28, 2022 -
Stock via Getty Images
Q&AWhy plasma derived therapies have a unique edge in rare diseases
Takeda's head of PDT R&D explains how the Japanese drug giant is advancing these emerging treatments.
By Kim Ribbink • Feb. 25, 2022 -
Permission granted by Guadalupe Hayes-Mota
ProfileGuadalupe Hayes-Mota's 'recipe' for tackling pharma's supply chain issues
A quest to expand access to medical treatment globally led to a new career path when Guadalupe Hayes-Mota left his biotech leadership roles to start his own company.
By Robin Robinson • Feb. 25, 2022 -
Diego Camargo/PharmaVoice
Podcast
Woman of the Week: Sumitovant's Chief Business Development and Commercial Officer Adele Gulfo
Adele Gulfo, chief business development and commercial officer at Sumitovant Biopharma, is leaning into her decades of experience to bring a future-focused approach to drug development.
By Taren Grom • Feb. 23, 2022 -
Stock via Getty Images
Eisai's mission to shake off Aduhelm's shadow and bring another AD drug to market
The company's senior VP of clinical research on how they're building off the science of Aduhelm to develop better Alzheimer's treatments.
By Kelly Bilodeau • Feb. 23, 2022 -
Stock via Getty Images
ProfileHow Veru is developing blockbuster drugs while avoiding biotech's 'valley of death'
Why sexual health and telemedicine are key to the company's goals in oncology.
By Meagan Parrish • Feb. 16, 2022 -
Stock via Getty Images
Q&AWinning buy-in from early stage biotech investors
The market is starting to cool down, but with the right strategies, biotechs can still attract early stage financing.
By Taren Grom • Feb. 11, 2022 -
Stock via Getty Images
OpinionIndustry executives on the milestone moments shaping pharma's future
Scientific, technological, and communication changes that are making a permanent impact on the industry.
By Taren Grom • Feb. 9, 2022 -
Permission granted by Mike Rea.
Q&AInnovation vs. invention
IDEA Pharma’s indices ranks how well companies turn ideas into commercialized pharma products.
By Taren Grom • Feb. 9, 2022 -
Retrieved from Google image.
Q&AGaining real-world results from a decentralized trial
Lark’s principal Investigator OraLee Branch hopes a DCT will lead the company to their true audience.
By Kelly Bilodeau • Feb. 8, 2022 -
Sergio Flores via Getty Images
Home is where the trial is
Facing pandemic disruptions, smaller biotechs are discovering the benefits and challenges of turning to decentralized clinical trials.
By Kelly Bilodeau • Feb. 7, 2022 -
Retrieved from MaxPixel.
Pharma's pain points with AI
Looking beyond the buzz and at the challenges associated with AI.
By Meagan Parrish • Feb. 7, 2022 -
Retrieved from Google image.
OpinionIndustry executives predict the next 'blue oceans' in pharma
Where life science leaders see breakthroughs happening in the industry.
By Taren Grom • Feb. 4, 2022 -
Courtesy of Web Sun
Komodo Health's partnership with Chan Zuckerberg Initiative gives 50 rare disease patient organizations access to next-generation analytics
With 330 million patient healthcare encounters in its database, Komodo assists advocacy organizations in gaining insights on specific patient populations.
By Robin Robinson • Feb. 3, 2022 -
Permission granted by Mary Harmon
Q&APTC's vice president of patient relations outlines the importance of patient input in rare disease R&D
You can't know what matters to rare disease patients unless you ask them.
By Kim Ribbink • Feb. 3, 2022 -
Permission granted by Peter Anastasiou
Q&A // First 90 DaysNew Capsida Biotherapeutics CEO Peter Anastasiou aims to bring AAV therapy to reality
Read what Capsida CEO Peter Anastasiou has planned for his new role.
By Taren Grom • Feb. 3, 2022 -
Pekic via Getty Images
OpinionTalent acquisition stays top of mind for pharma execs
From creating flexible work environments to looking outside the industry for new talent, pharma execs are shifting strategies to keep their teams afloat.
By Taren Grom • Feb. 1, 2022 -
Retrieved from Rare Disease.org.
Q&AFor the CEO of Travere, running a rare disease company is personal
To kick off Rare Disease month, we interview the CEO of Travere Therapeutics
By Kim Ribbink • Feb. 1, 2022 -
Q&A
Foghorn's CEO on why collaborations are key to unlocking precision medicine
With a major development deal under his belt, Adrian Gottschalk is helping the company advance its innovative platform.
By Robin Robinson • Jan. 28, 2022
Previous
